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Background: Mechanisms of Placental 
growth factor (PlGF)-mediated blood vessel 
formation are incompletely understood. 
Results: Plasmin cleaves the heparin binding 
domain of PlGF-2. 
Conclusion: Plasmin regulates PlGF-
2/Neuropilin-1-mediated tissue vascularization 
and growth. 
Significance: Plasmin-mediated carboxyl-
terminal processing of VEGF-family members 
may be considered as a principal mechanism to 
regulate their biological activity.  
 
SUMMARY 
Placental growth factor (PlGF) is a 
critical mediator of blood vessel formation, 
yet mechanisms of its action and regulation 
are incompletely understood. Here we 
demonstrate that proteolytic processing 
regulates the biological activity of PlGF. 
Specifically, we show that plasmin 
processing of PlGF-2 yields a protease-
resistant core fragment comprising the 
Vascular endothelial growth factor 
receptor-1 binding site, but lacking the 
carboxyl-terminal domain encoding the 
heparin binding domain (HBD) and an 8-
amino acid peptide encoded by exon 7. We 
have identified plasmin cleavage sites, 
generated a truncated PlGF118 isoform 
mimicking plasmin-processed PlGF, and 
have explored its biological function in 
comparison to PlGF-1 and -2. The 
angiogenic responses induced by the diverse 
PlGF forms were distinct. Whereas PlGF-2 
increased endothelial cell chemotaxis, 
vascular sprouting and granulation tissue 
formation upon skin injury, these activities 
were abrogated following plasmin digestion. 
Investigation of PlGF/Neuropilin-1 binding 
and function suggests a critical role for 
HBD/Neuropilin-1 interaction and its 
regulation by plasmin processing. 
Collectively, here we provide new 
mechanistic insights into the regulation of 
PlGF-2/Neuropilin-1-mediated tissue 
vascularization and growth. 
Placental growth factor (PlGF), a 
member of the Vascular endothelial growth 
factor (VEGF) family of growth factors, is a 
critical regulator of postnatal angiogenesis in 
various physiological and pathological 
conditions including repair of soft  
1-3
 and hard 
tissues 
4
, inflammation 
5
, and cancer 
6
. The 
exact molecular mechanisms by which PlGF 
regulates blood vessel formation are still not 
completely understood 
7
. PlGF has been 
reported to support the formation and 
maturation of new vessels by direct action on 
existing endothelial cells, but also promotes 
angiogenesis indirectly by inducing 
recruitment and survival of other cell types 
 http://www.jbc.org/cgi/doi/10.1074/jbc.M113.451831The latest version is at 
JBC Papers in Press. Published on May 3, 2013 as Manuscript M113.451831
 Copyright 2013 by The American Society for Biochemistry and Molecular Biology, Inc.
 at H
auptbibliothek U
niversitaet Zuerich Irchel. Bereich Forschung on M
arch 10, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Plasmin processing of PlGF 
 2 
involved in angiogenesis, such as mural cells, 
monocytes/macrophages and bone marrow-
derived precursor cells 
8-10
. 
Although PlGF and VEGF-A show 
only a 42% amino acid sequence identity, as 
well as significant functional differences, PlGF 
shares remarkable structural similarities with 
the extensively analyzed family member 
VEGF-A 
11
.  Comparative structure-function 
analysis between VEGF-A and PlGF might 
contribute to advance mechanistic insights into 
PlGF-mediated activities.  Generation of 
diverse VEGF-A isoforms, which are 
distinguished by the presence of C-terminal 
peptides encoded by exon 6, 7 and 8 of the 
vegf-a gene, are crucial for the diverse 
biochemical and functional properties of 
VEGF-A.  These include binding to cell 
surfaces and extracellular matrix (ECM) 
components, receptor-binding characteristics, 
endothelial cell adhesion and survival, as well 
as vascular branch formation 
11
.  Similarly to 
the generation of VEGF-A isoforms, in 
humans mRNA splicing of a single plgf gene 
gives rise to at least 4 different protein variants 
(PlGF-1 to -4), with PlGF-1 and -2 being the 
predominant isoforms expressed and studied so 
far 
12
.  In mice the plgf gene encodes only the 
PlGF-2 isoform 
13
. 
PlGF variants are homodimeric 
molecules, sharing a sequence encoded by 
exons 1-5 representing the VEGFR-1 binding 
sites and an 8-amino acid peptide encoded by 
exon 7.  PlGF-1 and -2 differ in the absence or 
presence of a domain encoded by exon 6, 
respectively, which exhibits affinity to 
heparin-sepharose and is referred to as 
heparin-binding domain (HBD) 
14
.  
Furthermore, cross-linking experiments and 
competitive binding studies on endothelial 
cells indicated that the HBD of PlGF-2 is 
critical for the interaction with the co-receptor 
neuropilin-1 (Nrp-1) 
15,16
.  The 
biological/functional consequences of PlGF-2 
binding with Nrp-1 and/or ECM components 
are still unclear. Likewise, functions of the 
amino acid sequence encoded by exon 7 have 
not been reported. 
Although mechanistically not yet 
completely understood, binding of VEGF-
A165 through its HBD to Nrp-1 was shown to 
promote VEGF-A165/VEGFR-2 complex 
formation and to sustain VEGFR-2 signaling 
and biological activities 
17,18
.  Furthermore, 
differential interaction of VEGF-A isoforms 
with various ECM components has been 
intensively analyzed.  All VEGF-A isoforms 
except the short VEGF-A121 and the VEGF-
Axxxb forms interact through their HBD 
encoded by exon 6a and 7 with 
heparin/heparan sulfate (HS); for VEGF-A165 
this feature has been shown to be essential for 
the establishment of a functional vascular 
system 
19,20
.  One could speculate on similar 
functions for the diverse PlGF isoforms for 
differential binding to matrix components 
and/or Nrp-1 interactions. 
In addition to differential mRNA 
splicing, proteolytic processing of long VEGF-
A isoforms has been shown to be an important 
regulatory mechanism to control VEGF-A 
activities 
21
.  Specifically, we and others have 
demonstrated the susceptibility of VEGF-A165 
to proteolytic cleavage by plasmin and 
metalloproteinases 
21-25
.  Both proteases 
generate a protease-resistant core fragment 
containing the VEGFR binding domain, but 
lacking the carboxyl-terminal domain coding 
for the HBD and the domain encoded by exon 
8.  Proteolytic processing of VEGF-A165 
substantially reduced and altered the 
angiogenic response during wound healing and 
tumor formation 
24,25
.  Whether the PlGF 
isoforms display analogous susceptibility to 
proteases has not been analyzed.  Here we 
investigated the hypothesis that PlGF is a 
substrate of plasmin and might be regulated in 
its biological activities by proteolytic 
processing.  We show that PlGF-2 is sensitive 
to plasmin processing and that truncation of 
PlGF-2 significantly impacts its HBD/Nrp-1-
mediated effects on angiogenesis.  Our 
findings unveil a dual control of PlGF activity 
by transcriptional regulation and proteolytic 
mechanisms.   
 
EXPERIMENTAL PROCEDURES  
Synthesis and purification of 
recombinant human PlGF variants - cDNAs of 
full-length PlGF-1 (Met-1 to Arg-131), PlGF-2 
(Met-1 to Arg-152) and a truncated version 
PlGF118 (Met-1 to Lys-118) were generated 
from human placenta and cloned into the 
eukaryotic expression vector pCEP V149 and 
pCEP V19.  For affinity purification cDNAs 
were fused either to an amino-terminal, 8x 
histidine tag (PlGF118) or an amino-terminal, 
8x histidine tag and carboxyl-terminal, double 
Strep tag (PlGF-1, PlGF-2). Proteins were 
produced in human embryonic kidney cells 
(HEK293 EBNA cells).  Recombinant PlGF 
isoforms were purified to 95% purity by 
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affinity chromatography using Strep-Tactin 
Superflow sepharose (PlGF-1 and PlGF-2; 
IBA BioTAGnology) or immobilized metal ion 
affinity chromatography using Ni-Sepharose 6 
Fast Flow (PlGF118; GE healthcare).  Protein 
identities were confirmed by Peptide Mass 
Fingerprinting.  Protein concentrations were 
determined by the BCA assay (Pierce) and 
ELISA (Quantikine human PlGF, R&D 
Systems) according to the manufacturer`s 
instructions. As indicated, in some experiments 
recombinant PlGF proteins were purchased 
and produced in Sf-9 insect cells (Reliatech). 
Sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) and 
immunoblotting - SDS-PAGE was performed 
following the protocol of Laemmli.  To 
analyze the sensitivity of PlGF isoforms to 
plasmin, PlGF proteins were incubated with 
wound exudate, human serum plasmin (0.02 
U/mL or serial dilutions as indicated) 
(Calbiochem), or α2-antiplasmin (Calbiochem) 
at 37C; at indicated time points, reactions 
were terminated by the addition of reducing or 
non-reducing  Laemmli buffer and heating to 
95°C.  The reactions were resolved on a 4-12% 
reducing Bis-Tris SDS-PAGE gel (NuPAGE, 
Invitrogen).  Integrity of PlGF isoforms was 
determined by silverstaining (SilverQuest
TM
, 
Invitrogen) or by detecting immunoreactive 
products with an anti-human PlGF monoclonal 
rabbit antibody directed against the first 20 
amino-terminal amino acids of human PlGF 
(Reliatech).  Bound primary antibody was 
detected using an anti-rabbit-HRP conjugated 
secondary antibody (DAKO A/S). To assess 
Nrp-1 expression in PAE and PAE/Nrp-1 cells, 
cell lysates were normalized to 1000 µg total 
protein, incubated with ConA-Sepharose beats 
(Amersham Biosciences) to enrich 
glycosylated proteins following the 
manufacturer’s instructions; the eluted fraction 
was analyzed by immunoblotting using a 
mouse-anti-human Nrp-1 (A12) antibody 
(Santa Cruz Biotechnology) and an anti-
mouse-HRP conjugated secondary antibody 
(DAKO A/S). 
To analyze signal transduction, 
endothelial cells were starved and incubated 
with PlGF variants (2.5 nM) in EBM-2 
(growth factor free, 0.1% FCS) (Invitrogen), 
VEGF-A165 (1.8 nM) (produced in Sf9 insect 
cells, Reliatech) or starvation medium for 
indicated time periods.  Cells were lysed, 
samples were resolved in 4-12% Bis-Tris SDS-
PAGE gel and immunoblotted with anti-
phospho-focal adhesion kinase (Tyr576/577), 
anti-phospho-Akt (Ser473), anti-phospho-Erk-
1/-2, (Thr202/Tyr204), anti-total Akt, anti-total 
Erk-1/-2, anti-β-actin (all Cell Signaling 
Technologies), anti-phospho-VEGFR-1 
(Tyr1213) (Millipore), anti-total-VEGFR-1 
(Millipore) or anti-Nrp-1 (Santa Cruz 
Biotechnology). Detection was accomplished 
using the enhanced chemiluminescense 
western blot detection system (ECL, 
Amersham Bioscience). Densitometric 
analysis of phospho-signal intensity was 
performed using the ImageJ 1.44p software. 
The signal of pErk, pAkt or pFAK was 
normalized to the corresponding total Erk, Akt 
or -actin signal, respectively. Multiple 
Western blots (3) were performed.  
Mass spectrometric analysis – PlGF-2 
expressed in HEK293 cells (25 μg in 200 μL 
50 mM Tris/HCl, pH 8) was incubated with 
Ni-sepharose beats (15 min, RT) to allow 
binding to the N-terminal his-tag, followed by 
incubation in plasmin (final concentrations: 
0.04 or 0.008 U/mL in plasmin buffer 50 mM 
Tris/HCl, pH 8, 37°C, 5 or 30 min); beats were 
collected by centrifugation (5 min, 13.500 rpm, 
4°C), and the supernatants were analyzed by 
LC-MS/MS.  Liquid chromatography (LC)-MS 
data were acquired on a Q-TofII quadrupole-
TOF mass spectrometer (Micromass) equipped 
with a Z spray source. Samples were 
introduced by an Ultimate Nano-LC system 
(LC Packings) equipped with the Famos 
autosampler and the Switchos column-
switching module. The column setup 
comprises a 0.3-mm-by-1-mm trapping 
column and a 0.075-by-150-mm analytical 
column, both packed with 3 µm Atlantis dC18 
(Waters). Samples were diluted 1:10 in 0.1% 
TFA. A total of 10 µL was injected onto the 
trap column and desalted for 1 min with 0.1% 
TFA and a flow rate of 10 µL/min. The 10 port 
valve switched the trap column into the 
analytical flowpath, and peptides were eluted 
onto the analytical column by using a gradient 
of 2% acetonitrile (ACN) in 0.1% FA to 40% 
ACN in 0.1% FA over 65 min and a column 
flow rate of ca. 200 nL/min, resulting from a 
1:1,000 split of the 200 µL/min flow delivered 
by the pump. The electrospray ionization (ESI) 
interface comprised an uncoated 10 µm i.d 
PicoTip spray emitter (New Objective) linked 
to the HPLC flowpath using a 7 µL dead 
volume stainless steel union mounted onto the 
PicoTip holder assembly (New Objective). 
Stable nanospray was established by the 
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application of 1.7 to 2.4 kV to the stainless 
steel union. The data-dependent acquisition of 
MS and tandem MS (MS/MS) spectra was 
controlled by the Masslynx  4.0. Survey scans 
of 1.4 s covered the range from m/z 400 to 
1,400. Doubly and triply charged ions rising 
above a given threshold were selected for 
MS/MS experiments. In MS/MS mode, the 
mass range from m/z 40 to 1,400 was scanned 
in 1.4 s, and 4 scans were added up for each 
experiment. Micromass-formatted peak lists 
were generated from the raw data by using the 
Proteinlynx software module.  A database 
search using a local installation of MASCOT 
1.9 and a custom database containing the 
sequence of recombinant PIGF-2 was used for 
a fast identification of PIGF-2 derived 
peptides. No enzyme specificity was used for 
the database search. Since it was expected, that 
the sequence stretch of interest contains a pair 
of oxidised cysteines, cysteine oxidation was 
allowed as optional modification. Results 
reported by the search engine were verified by 
manual inspection of the deconvo. 
Surface Plasmon Resonance 
spectroscopy - Binding experiments were 
performed by surface plasmon resonance 
measurements on a Biacore 3000 instrument 
(Biacore Inc.) at 25°C, following a well 
established procedures 
26
.  Briefly, to assess 
the binding capacity of the various PlGF 
isoforms to Nrp-1 in dependence to heparin, a 
CM5 sensor surface was activated by use of 
EDC/NHS and coupling buffer in a ratio of 1:1 
as activating reagents.  The degree of coupling 
was set to approximately 1500 RU.  
Remaining reactive groups were inactivated 
with ethanolamine, and PlGF variants were 
coupled on chip surface at a flow rate of 
5 μL/min.  The following binding experiments 
with human Nrp-1 (extracellular domain, 
Phe22-Lys644; BD Biosciences) as soluble 
analyte were performed with various 
concentrations (1 to 300 nM in HEPES 
running buffer).  The analyte was passed over 
the sensor chip with a constant flow rate of 30 
μL/min for 300 seconds, dissociation was 
measured over 500 seconds.  Between different 
experimental cycles, the bound proteins were 
washed from the sensor surface with 2 M NaCl 
in running buffer. In a second experimental 
setting, Nrp-1 was coupled to the sensor chip 
and the degree of coupling was set to 1500 
RU, whereas 1 to 300 nM of PlGF was used as 
soluble analyte. Fittings of the data, overlay 
plots and calculation of KD-values were done 
with BIAevaluation software 4.1 estimating a 
1:1 model. 
Binding of PlGF forms to heparin - 
The three proteins were dialyzed against the 
loading buffer (50 mM NaC1, 20 mM Tris-
HCl, pH 7.4), and 1 mg each was applied onto 
a heparin-Sepharose CL-6B column (GE 
healthcare). After five washes with loading 
buffer, the columns were eluted stepwise with 
increasing salt concentration (0.1, 0.2, 0.4, 0.5, 
0.75, 1 and 2 M NaC1 in 20 mM Tris-HC1, pH 
7.4) and the samples were analyzed by SDS-
PAGE. 
Circular dichroism (CD) spectroscopy 
- CD spectra (180-260 nm) were recorded at 
100 nm/min using a Jasco-J715 
spectropolarimeter and a thermostated 0.1 cm 
path length quartz cell (20°C, 5 accumulations 
each). Data point resolution and bandwidth 
were set to 0.2 nm, sensitivity to 50 mdeg. CD 
spectra of samples containing 5 μM PlGF 
(PlGF-1, PlGF-2 or PlGF118) in PBS were 
measured, background-corrected, converted to 
mean molar residue ellipticity and data were 
evaluated using J-715 for Windows Standard 
Analysis software.  
Chemotaxis assay - Chemotaxis assays 
were performed using a Boyden chamber 
system with filter inserts of 8 µm pore size 
(Millipore). Filters were pre-coated with 
collagen (BD).  Medium supplemented with or 
without PlGF isoforms (2.56 nM) was added 
into the lower chamber, whereas 2.5 x 10
5
 cells 
were seeded into the upper chamber.  Medium 
supplemented with 10% FCS or VEGF-A165 
(1.79 nM) (Reliatech) served as positive 
control.  After 4.5 hours (37 °C) cells on the 
lower face were fixed and stained with a 
variant of Romanowski staining (Quickdiff, 
Behring) and analyzed by light-microscopy; 
cell number was determined in 10 high power 
fields per filter (200-fold magnification).  
3D Spheroid-sprouting Assay - HUVE 
cells (1000 cells/well) were seeded in 20% 
methylcellulose/80% growth medium (100 µL) 
into a 96-roundbottom plate (NUNC) to induce 
spheroid formation. After 24 hours of 
incubation (37°C), spheroids were harvested 
and 50 spheroids/gel were seeded into 500 µL 
of a non-polymerized collagen gel (2 mg/mL) 
in 24-well plates.  Following polymerization, 
PlGF variants (3.66 nM) or VEGF-A165 (1 
nM) as positive control were added to the gel.  
After 24 hours incubation at 37°C, 15 
randomly chosen spheroids were analyzed for 
each protein at 100-fold magnification (Nikon 
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bright field microscope).  Cumulative 
sprouting length and number of 
sprouts/spheroid was measured using the 
ImageJ software. 
Animals and wounding experiments -
C57BLKS/J-m+/+Lepr
db/db 
mice (Jackson 
Laboratory, male, 10-12 weeks of age) were 
caged individually under standard pathogen-
free conditions and two independent wound 
healing experiments were performed as 
previously described 
25
. Briefly, mice were 
anesthetized, 4 full-thickness punch-biopsy 
wounds were created on the back of the mouse 
and treated locally for the following 6 days by 
either applying PlGF variants (2.5 µM in PBS) 
or vehicle control (PBS).  Solution was 
allowed to adsorb for at least 1 hour before the 
animal was placed back into its cage.  For 
histological analysis wound tissues were 
excised and the wound area bisected in 
caudocranial direction; the tissue was fixed 
(4% paraformaldehyde) or embedded in OCT 
compound (Tissue Tek), immediately frozen in 
liquid nitrogen, and stored at -80C.  
Histological analysis was performed on serial 
sections (6 µm). 
Histology, immunohistochemistry and 
morphometric analysis - Cryosections were 
fixed in acetone, blocked (3% BSA), incubated 
with antisera against murine CD31 (BD 
Biosciences), desmin (DakoCytomation), and 
F4/80 (Dianova); bound primary antibodies 
were detected using an ALEXA Fluor 488-
conjugated polyclonal goat anti-rat antibody 
and an ALEXA Fluor 594-conjugated 
polyclonal goat anti-mouse antibody 
(Invitrogen); nuclei were stained with DAPI.  
As a control for specificity primary antibodies 
were omitted and replaced by irrelevant 
isotype-matched antibodies. 
Immunofluorescence/immunohistochemical 
microscopy was conducted at indicated 
magnifications (Microscope Eclipse 800E; 
Nikon), and morphometric analysis was 
performed on digital images as recently 
described 
25
. 
Human wound exudates - Wound 
exudate was obtained from patients presenting 
with non-healing skin ulcers due to venous 
insufficiency (n=7) or from patients with 
normally healing acute cutaneous wounds at 
indicated time points post injury (day 2 n=10, 
day 7 n=5, day 14 n=7; excisional wounds of 
the lower leg awaiting wound closure by 
secondary intention); in addition blood serum 
was obtained from 15 patients.  Exudate was 
harvested and tested for plasmin activity as 
previously described 
23,26
. PlGF content in 
serum samples or wound exudates was 
determined by ELISA (Quantikine human 
PlGF immunoassay, R&D Systems). 
Statistical analysis - Data were 
summarized by mean ± SEM. Location 
differences were assessed by analysis of 
variance and Tukey post-hoc tests for pairwise 
comparisons. Thus, the type I error is strongly 
controlled, at least pertaining to specific 
families of (pairwise) hypotheses. Moreover, 
in case the SEM clearly increased with the 
mean (based on Bartlett's test for equal 
variances), a log-transformation was applied in 
order to stabilize the variance. Statistical 
significance (adjusted for multiplicity) was 
graded according to * < 0.05, ** < 0.01, or *** 
<0.001. All statistical analyses were performed 
using GraphPad Prism 5 (GraphPad Software 
Inc.). 
 
RESULTS 
PlGF is cleaved by plasmin - To 
investigate the hypothesis that PlGF might be a 
substrate for the serine protease plasmin, 
PlGF-1 and PlGF-2 were incubated with 
plasmin and samples were subjected to gel-
electrophoresis and analyzed by silver-staining 
(Fig. 1A-C) and Western blotting (Fig. 1D).  In 
non-reducing conditions dimeric PlGF-2 
migrated with a molecular weight of 
approximately 42 kDa (Fig. 1A).  Extended 
incubation of PlGF-2 with plasmin for 4 hours 
resulted in its fragmentation and formation of a 
protease-resistant cleavage product of 
approximately 32 kDa.  In reducing conditions, 
the PlGF-2 monomer exhibited an 
electrophoretic mobility shift from 23 kDa to 
approximately 16 kDa following plasmin-
mediated digestion (Fig 1B).  Cleavage 
products migrating below 16 kDa could not be 
detected.  Plasmin-mediated fragmentation of 
PlGF-2 was inhibited by the plasmin inhibitor 
2-antiplasmin (Fig. 1B).  In reducing 
conditions, monomeric PlGF-1 migrated with a 
molecular weight of 17 kDa, with a shift of 
approximately 1-2 kDa following plasmin 
digestion (Fig. 1C).  The generation of a major 
protease-resistant fragment with similar 
electrophoretic mobility for PlGF-1 and -2 as 
well as the detection of this protease-resistant 
16 kDa fragment with an antibody raised 
against the amino-terminal domain of PlGF, 
suggests carboxyl-terminal cleavage in both 
proteins (Fig. 1D).  A dose-response analysis 
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indicated that plasmin-mediated cleavage of 
PlGF-2 occurred in multiple stages (Fig. 1D). 
To examine whether PlGF proteolysis 
might be a biological relevant event in the 
human system, we determined the 
concentration and integrity of PlGF in 
exudates obtained from normal healing or non-
healing chronic human wounds.  Wound 
exudate is the interstitial fluid of injured tissue 
that reflects the metabolic condition of the 
wound microenvironment and has been proven 
to be useful for identification of factors 
involved in wound healing physiology and 
pathology 
27,28
.  As quantified by ELISA, in 
both exudates obtained from healing and non-
healing wounds the mean concentration of 
PlGF was significantly increased (at least 25-
fold) as compared to the mean concentration of 
plasma serum levels of 26 pg/mL, arguing for 
local PlGF expression at the wound site (Fig. 
1E).  PlGF concentrations were similar in 
healing and non-healing wounds.  To analyze 
the integrity of PlGF protein in the wound 
environment, recombinant PlGF-2 was spiked 
into wound exudates obtained from normal 
healing or non-healing wounds and samples 
were subjected to Western blot analysis in 
reducing conditions (Fig 1F).  Whereas in 
exudates obtained from healing wounds to 
large extent PlGF-2 maintained its stability, in 
exudates obtained from non-healing wounds 
PlGF-2 underwent a gradual degradation 
resulting in the formation of a protease-
resistant fragment with an approximate 
molecular weight of 16 kDa after 2 hours of 
incubation with exact the same electrophoretic 
mobility than plasmin digested PlGF-2 (Fig. 
1F).  Fragmentation of PlGF-2 (produced in 
human embryonic kidney 293 EBNA cells) in 
exudates obtained from non-healing wounds 
could be partially rescued by pre-incubation 
with 2-antiplasmin (Fig. 1G). As shown 
previously 
27,28
, in this study plasmin activity 
was significantly increased in exudates 
obtained from chronic versus healing wounds 
plasmin activity in chronic exudates (n=3) 
mean 27 mU/mL SD 7.8, in healing exudates 
(n=4) mean 17 U/mL SD 5.7; p = 0.05.  
Collectively, these findings suggest that 
proteolytic processing of the carboxyl-
terminus in PlGF occurs during tissue repair 
and is differentially regulated in healing and 
non-healing conditions. 
Processing of PlGF-2 by plasmin 
results in cleavage of the HBD - To identify 
the plasmin cleavage sites in PlGF-2 we used 
LC-MS/MS analysis.  Consistent with the 
Western blot analysis that suggested a multi-
stage cleavage event, LC-MS/MS analysis 
revealed several fragments that indicate 
cleavage sites within the HBD at residues 
Arg151, Lys136, Arg134, Lys131, Lys127, 
and Lys118 (Fig. 2).  Extended plasmin 
digestion therefore results in a complete 
degradation of the HBD, with Lys118 
representing position P1 of the cleavage site 
closest to the amino-terminus, and the plasmin-
resistant amino-terminal fragment PlGF1-118 
representing the VEGFR-1-binding domain.  
Although we did not subject plasmin-digested 
PlGF-1 fragments to LC-MS/MS analysis, 
several arguments suggest that also in PlGF-1 
the position Lys118 is the plasmin cleavage 
site closest to the amino-terminus: first, the 
cleavage site Lys118-Met119 is localized 
within the domain encoded by exon 5, which is 
equivalent in PlGF-1 and -2; secondly, 
cleavage at position Lys118 would be 
consistent with the electrophoretic mobility 
shift of 1-2 kDa under reducing conditions 
following plasmin processing of PlGF-1 (Fig. 
1C).  Notably, the plasmin cleavage site for 
VEGF-A165 has also been mapped within 
exon 5 (Fig. 2A) 
22,23
.   
Plasmin-cleavage attenuates PlGF-2-
mediated VEGFR-1 phosphorylation - To 
evaluate the functional impact of plasmin-
mediated carboxyl-terminal processing of 
PlGF, we generated constructs of PlGF-1, 
PlGF-2 and a truncated isoform that mimicked 
the plasmin-resistant PlGF fragment 
(PlGF118).  These constructs were used to 
produce recombinant proteins in human 
embryonic kidney (HEK) 293 EBNA cells.  To 
assess proper folding of the PlGF-variants, we 
analyzed dimerization and secondary structure 
properties by SDS-PAGE analysis and CD-
spectroscopy.  In non-reducing conditions, 
PlGF-2, PlGF-1 and PlGF118 migrated with a 
molecular weight of approximately 65-68 kDa, 
58-60 kDa, and 54-55 kDa, respectively (Fig. 
3A).  In reducing conditions, monomers of 
PlGF-2, PlGF-1 and PlGF118 exhibited a 
molecular weight of approximately 38-39 kDa, 
36-37 kDa, and 32-33 kDa, respectively (Fig. 
3A).  Differences in elecrophoretic mobility of 
recombinant proteins depicted in figure 1 and 3 
are due to differences in posttranslational 
modifications (e.g. glycosylation) and 
histidine/double Strep-tag expression.  All 
isoforms showed a comparable degree in their 
ellipticity, indicating that loss of the carboxyl-
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terminus does not affect the secondary 
structure of PlGF isoforms (Fig. 3B). As 
revealed by Western blot analyses, all isoforms 
resulted in Tyr1213 phosphorylation of VEGFR-
1 when compared to stimulation with 0.1% 
FCS, although weaker in PlGF-1 and PlGF118 
when compared to PlGF-2 (Fig. 3C).   
Plasmin-cleavage attenuates PlGF-2-
mediated endothelial cell chemotaxis and 
vascular sprouting - To analyze the functional 
impact of plasmin-processing for PlGF, the 
chemotactic activity of PlGF variants on 
endothelial cells was analyzed in a Boyden 
chamber assay.  Previous studies reported on 
equal chemotactic potency of PlGF-1 and -2 
(produced in Sf9 insect cells) in bovine aortic 
arch-derived endothelial cells 
16
.  Here we used 
porcine aortic endothelial cells (PAE) stably 
transfected with the human Nrp-1 receptor 
(PAE/Nrp-1) or untransfected cells lacking 
Nrp-1 expression (Fig. 4A) to examine the 
effect of diverse PlGF variants.  Nrp-1 
transfected PAE cells treated with PlGF-2 
(expressed in Sf9 insect cells) exhibited at least 
a 2-fold higher chemotactic response as 
compared to cells treated with PlGF-1 or 
control cells (Fig 4B).  Pre-incubation of 
PlGF-2 with plasmin resulted in a significant 
loss of its chemotactic activity that was partly 
rescued by α2-antiplasmin.  Both PlGF-1 and 
PlGF-2 were unable to induce chemotaxis in 
untransfected cells lacking Nrp-1 expression 
(Fig 4B).  Repeating the experiment with PlGF 
isoforms produced in HEK293 cells and 
extending the analysis on HUVE cells 
substantiated the critical role of the HBD for 
endothelial cell chemotaxis.  In both PAE/Nrp-
1 and HUVE cells, chemotactic activity was 
significantly increased in response to PlGF-2 
as compared to PlGF-1 and PlGF118 (Fig. 4C, 
D).   
We next tested the role of plasmin 
processing of PlGF in endothelial sprout 
formation using a 3D-spheroid outgrowth 
assay in type collagen I gels.  Both the 
cumulative sprouting length (reflecting sprout 
outgrowth) and the number of sprouts 
(reflecting sprout induction) per spheroid were 
significantly increased by PlGF-2 treated 
cultures as compared to controls (Fig. 4E, F).  
Although PlGF-1 and PlGF118 also revealed 
stimulating activity on sprout formation when 
compared to controls, the overall response was 
weaker when compared to PlGF-2 and the 
response on sprout induction did not reach 
statistical significance when compared to 
controls.  Of note, after 24 hours of treatment, 
all PlGF-treated spheroids revealed a greater 
stability as compared to control cultures, 
suggesting that PlGF acts as a survival factor 
for endothelial cells, independently of the 
HBD and/or the carboxyl-terminal domain 
encoded by exon 7. 
The HBD of PlGF-2 is critical for its 
repair promoting activities in diabetic mice -
Further exploration of biological effects of 
plasmin processing of PlGF was performed in 
an in vivo wound healing assay.  Vascular 
growth is profoundly involved in effective 
tissue repair and has been shown to be 
significantly attenuated in preclinical models 
of impaired healing such as diabetic mice and 
chronic skin ulcers in humans 
23,25
.  Full 
thickness excisional skin wounds were created 
on the back of diabetic mice (db/db mice) and 
the repair response was characterized 
following local treatment with repetitive 
applications of PlGF isoforms (2.5 M) or 
vehicle control.  Quantitative analysis of 
granulation tissue formation (H&E stained 
wound sections), macrophages (F4/80 positive 
cells), vascular density and perivascular cells 
(CD31/desmin double staining) present in 
granulation tissue showed that in PlGF-2 
treated wounds the amount (Fig. 5), cellularity 
and vascularization of granulation tissue (Fig. 
6) were significantly increased at day 10 and 
14 post injury, as compared to PlGF-1, 
PlGF118 or vehicle treated wounds.  
Granulation tissue formation and 
vascularization were also increased in response 
to PlGF-1 and PlGF118 as compared to vehicle 
controls, however these effects were minor and 
did not reach statistical significance.  
Furthermore, whereas in PlGF-1- and 
PlGF118-treated wounds the vascular density 
decreased towards day 14 post injury, the 
increased vascular density in PlGF-2-treated 
wounds sustained until day 14. The ratio of 
desmin/CD31-double stained vascular 
structures within the granulation tissue was 
significantly increased in response to PlGF-2 
as compared to PlGF-1-, PlGF118- and 
vehicle-treated wounds at day 10 and 14.  
These findings indicate an enhanced coverage 
of vascular structures by perivascular cells in 
PlGF-2-treated wounds and suggest increased 
stability/maturation of PlGF-2-induced blood 
vessels at the wound site (Fig. 6B). Wound 
closure kinetics was not significantly altered in 
PlGF treated wounds at day 10 and 14 post 
injury (data not shown). 
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Plasmin processing of PlGF-2 
abrogates its binding capacity to heparin and 
Neuropilin-1 - Next we evaluated the impact of 
plasmin processing upon the binding capacity 
of PlGF to heparin and to the co-receptor Nrp-
1.  As shown by affinity purification PlGF-2 
binds strongly to heparin (Fig 7A), confirming 
earlier studies that reported binding of PlGF-2 
to heparin-sepharose 
14
.  Importantly, PlGF-1 
and PlGF118 do not interact with heparin (Fig. 
7A).  As revealed by plasmon resonance 
spectroscopy, binding of PlGF-2 to the 
immobilized Nrp-1 extracellular domain was 
clearly concentration dependent and the 
calculated KD was 0.1 M (Fig. 7B). Plasmin 
digestion of PlGF-2 abrogated interaction with 
Nrp-1. PlGF-1 did not bind to Nrp-1.  Binding 
characteristics for Nrp-1 were confirmed for 
all PlGF variants by inverted settings using 
Nrp-1 as soluble analyte (data not shown).   
The HBD differentially regulates 
PlGF-2-induced phosphorylation of the focal 
adhesion kinase but does not modulate Erk-1/-
2 or Akt-mediated signaling - We further 
explored downstream pathways that might 
mediate the differential effects in response to 
plasmin processed PlGF-2.  We focused the 
analysis on signaling molecules previously 
shown to be critically involved in PlGF-
mediated cell functions.  Stimulation of HUVE 
cells with either PlGF-2 or PlGF118 resulted in 
rapid phosphorylation of Erk-1/-2 and Akt, 
which was similar in signal intensity for both 
molecules (Fig. 8A).  Also, overexpression of 
Nrp-1 in PAE cells did not alter the signal 
strength for Erk-1/-2 and Akt activation in 
response to PlGF-2 (Fig. 8B).  Based on these 
findings it seems unlikely that Erk/Akt 
activation is involved in differential 
endothelial cell activities in response to PlGF-
2 and PlGF118 stimulation.  We then 
investigated the involvement of focal adhesion 
kinase (FAK) signaling in response to PlGF 
stimulation.  Whereas stimulation with PlGF-2 
provoked an increased and sustained 
phosphorylation signal of FAK, the activation 
signal was substantially weaker in response to 
PlGF118 (Fig. 8C).  Furthermore, PlGF-2-
mediated activation of FAK was pronounced 
in PAE-Nrp-1 transfected cells as compared to 
cells lacking Nrp-1.  Together, our findings 
propose a critical role of PlGF-2/Nrp-1 
interaction for FAK activation. 
 
 
 
DISCUSSION 
In this study we demonstrated that 
PlGF-1 and -2 are substrates for plasmin and 
that plasmin-catalyzed cleavage results in loss 
of the carboxyl-terminal domain in both 
proteins.  Plasmin-mediated processing of 
PlGF-2 significantly decreased its binding to 
heparin and Nrp-1, and substantially attenuated 
its pro-angiogenic activities.  Our findings 
provide novel mechanistic insights into the 
regulation of PlGF-2/Nrp-1 interactions by 
proteolytic processing and important biological 
consequences of this event for tissue 
vascularization and growth. 
We and other investigators previously 
demonstrated the critical role of plasmin 
processing of VEGF-A165 for its biological 
behavior 
21,22,25
.  In addition, plasmin-mediated 
processing has been reported to be critical for 
VEGF-C and –D activation, which are 
primarily involved in lymphangiogenesis 
29
.  
Here we show that kinetics and structural 
consequences of plasmin-mediated processing 
of PlGF-2 are similar to plasmin-mediated 
cleavage of VEGF-A165.  Both proteins reveal 
gradual degradation following exposure to 
plasmin, with the highest proteolytic 
sensitivity within their HBD localized at the 
carboxyl-terminus.  In both proteins the 
cleavage site closest to the amino-terminus is 
localized within the domain encoded by exon 
5, in close proximity to the cysteine residues 
critical for the formation of intrachain disulfide 
bonds.  Thus, for VEGF-A165 and PlGF-2 
plasmin-mediated cleavage yields an amino-
terminal homodimeric VEGF-A110 and 
PlGF118, respectively, comprising the VEGFR 
binding domain and lacking the carboxyl-
terminal domains.  Plasmin processing 
apparently does not substantially affect folding 
and dimerization of either protease-resistant 
fragment, which are still capable of activating 
VEGFRs although at different levels.  
Therefore, we propose to consider the 
carboxyl-terminal processing of these two 
VEGF-family members by plasmin as a 
principal mechanism to regulate their 
biological activity. 
Plasmin processing revealed different 
functional consequences for PlGF-1 and -2.  
Whereas plasmin digestion of PlGF-2 
significantly attenuated endothelial cell 
chemotaxis, vascular sprouting and granulation 
tissue formation during tissue repair, biological 
responses to PlGF-1 were similar to PlGF118 
or vehicle control stimulated cells/tissues.  
 at H
auptbibliothek U
niversitaet Zuerich Irchel. Bereich Forschung on M
arch 10, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Plasmin processing of PlGF 
 9 
Therefore, effects of plasmin digestion on the 
biological activities of PlGF-1 appear to be 
minimal.  These findings strongly indicate that 
most of the PlGF-2-stimulated activities we 
observed in our studies are dependent upon the 
HBD encoded by exon 6. 
 To examine the molecular mechanisms 
underlying the loss of PlGF-2-mediated 
responses following plasmin digestion, we 
investigated several potential mechanisms.  
First, we assessed whether endothelial cell 
stimulation with different PlGF variants leads 
to differences in VEGFR-1 tyrosine 
phosphorylation and activation of known 
downstream mediators.  PlGF is capable of 
signaling directly through VEGFR-1, and 
several VEGFR-1 tyrosine phosphorylation 
sites in endothelial cells have been reported to 
be activated upon stimulation with PlGF-2 
8,30
.  
However, we could not find a systematic 
analysis in the literature investigating the 
pattern and function of different tyrosine 
phosphorylation sites of VEGFR-1 in response 
to diverse PlGF isoforms.  Here we show that 
following stimulation of HUVE cells, all PlGF 
variants, although weaker in the absence of 
sequences encoded by exon 6 and/or 7, had the 
potency to phosphorylate Tyr1213 and to 
equally activate downstream mediators 
including Erk and Akt.  Therefore, this 
pathway is unlikely to explain the different 
biological activities we found in response to 
various PlGF isoforms.  But these results on 
downstream signaling support the observation 
that all PlGF variants mediated stability of 
spheroid structures when compared to vehicle 
control, and indicate that PlGF-mediated 
endothelial cell survival is independent of the 
HBD and/or the carboxyl-terminal domain 
encoded by exon 7 as well as binding to Nrp-1 
and/or heparin.  Furthermore, our findings 
suggest that PlGF-2-mediated activation of 
Erk-1/-2 is independent of Nrp-1 binding, 
which is paralleled by recent reports 
demonstrating that VEGF-A165-mediated 
activation of Erk-1/-2 is independent of Nrp-1 
31
.  At this stage we cannot exclude that other 
VEGFR-1 tyrosine residues than Tyr1213 might 
be differentially activated by different PlGF 
variants and this aspect requires more detailed 
examination in future studies.   
 Secondly, we investigated functional 
consequences of differential binding of PlGF 
variants to the co-receptor Nrp-1.  The exact 
mechanism how Nrp-1 acts on endothelial cell 
functions is still not resolved and so far most 
of the functional studies were performed with 
VEGF-A165 
32,33
. Based on those studies it 
was proposed that Nrp-1 acts as a co-receptor 
for VEGF-A165, enhancing VEGF binding to 
VEGFR-2, and thus increasing VEGFR 
signaling.  More recent studies indicated that 
rather than affecting VEGFR-2 activity 
directly, Nrp-1 is likely to modulate signaling 
kinetics and the activation of specific signal 
output via VEGFR-2 
17
. The short carboxyl-
terminal sequence of VEGF-A encoded by 
exon 8a (KPRR) was identified as a critical 
sequence to direct binding and specificity 
towards Nrp-1 
17,34-37
. Interestingly, against 
common knowledge, recently it was shown 
that also VEGF-A121 binds directly to Nrp-1 
38
 through exon 8a 
39
.  In contrast to the 
situation with VEGF-A165, VEGF-A121 was 
not able to bridge VEGFR-2/Nrp-1 interaction 
and to induce the formation of a VEGFR-
2/Nrp-1 complex 
38
.  The understanding for 
PlGF/Nrp-1 interaction is so far based on 
earlier cross-linking experiments and 
competitive binding analysis on endothelial 
cells that identified the HBD of PlGF-2 as an 
epitope for the Nrp-1b1b2 domain, whereas 
PlGF-1 revealed no binding to Nrp-1 
15,16
.  
Interestingly, the short carboxyl-terminal 
sequence of PlGF-1 and -2 encoded by exon 7 
has high sequence homology with exon 8a of 
VEGF-A.  In light of the critical role of exon 
8a of the vegf-a gene for Nrp-1 binding 
17,34-37
, 
we hypothesized whether similarly to VEGF-
A121, also PlGF-1 might be able to bind to 
Nrp-1.  Using surface plasmon resonance 
spectroscopy, here we demonstrated that PlGF-
2 but not PlGF-1 specifically and strongly 
binds to Nrp-1.  Furthermore, we show that 
plasmin processing of PlGF-2 completely 
abrogates binding of PlGF-2 to Nrp-1.  
Thereby, our findings support earlier cross-
linking experiments and corroborate the 
critical role of exon 6 and not exon 7 as Nrp-1 
binding sequence in PlGF-2. Given the 
sequence homology between the basic peptides 
encoded by exon 8a and exon 7 of vegf-a and 
plgf, respectively, we believe this is an 
interesting finding unraveling a potential 
difference in binding of PlGF and VEGF-A to 
Nrp-1, and merits further investigation in 
future studies. 
Our findings indicate a critical role of 
PlGF-2/Nrp-1 binding for PlGF-2 function.  
FAK activation is closely linked to cell 
survival and migration in endothelial cells 
40
.  
Interestingly, a recent report demonstrated the 
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critical role of VEGF-A165 binding to Nrp-1 
for FAK activation, endothelial cell migration 
and tube formation 
31
.  We hypothesized that 
increased FAK activation in response to PlGF-
2/Nrp-1 stimulation mediates the findings of 
superior PlGF-2 pro-angiogenic activities over 
those of PlGF-1 or PlGF118.  Here we 
substantiated this hypothesis by showing, that 
phosphorylation of FAK was increased and 
sustained by PlGF-2 when compared to 
PlGF118.  Furthermore, this effect was 
enhanced in Nrp-1-transfected PAE cells when 
compared to cells lacking Nrp-1 expression.  
Thus, our findings indicate an important role 
for PlGF-2 binding to Nrp-1 in pathways 
controlling actin cytoskeletal rearrangements 
critical for cell migration and vessel growth. 
Third, differential interaction of 
VEGF-A isoforms with diverse components of 
the ECM, in particular glycosaminoglycans, 
has been shown to be critical for VEGF-A-
mediated biological activities 
21
.  Here we 
provide evidence that PlGF-2, but neither 
PlGF-1 nor PlGF118 binds strongly to heparin 
and that this interaction is entirely abrogated 
by plasmin processing.  These findings 
substantiate earlier studies demonstrating high 
affinity of PlGF-2 to heparin-sepharose 
14
.  At 
this stage we can only speculate on potential 
functions of PlGF-2/heparin binding for 
angiogenic processes.  As reported for VEGF-
A165, PlGF-2/heparin interactions might allow 
for the formation of growth factor gradients 
which are critical for vascular sprouting and/or 
modulate Nrp-1-mediated activities 
40,41
. 
Finally, our findings raise the general 
question on the biological role of PlGF-1 per 
se, and on the dual generation of a short PlGF 
isoform lacking the HBD by either 
transcriptional control and/or proteolysis.  
Contrarily to the generation of diverse PlGF 
isoforms by differential mRNA splicing in 
humans, in mice PlGF-2 is the only isoform 
identified so far 
13
.  Hence, our findings 
suggest that in mice modification of PlGF-2 
activity by proteolytic processing provides a 
unique mechanism to control activities 
mediated by the carboxyl-terminal domain.  In 
humans, next to mRNA splicing of the plgf 
gene, proteolytic processing of PlGF isoforms 
provides an additional mechanism to control 
processes mediated by the carboxyl-terminal 
domain.  Our findings indicate that the impact 
of proteolytic processing, specifically on 
PlGF-2 becomes particularly critical in 
conditions of high/uncontrolled proteolytic 
activity, as e.g in degenerative conditions such 
as chronic wounds associated with diabetes 
mellitus, age and vascular disease.  In fact, 
here we showed that proteolytic processing of 
PlGF is increased in human chronic venous 
ulcers when compared to healing wounds.  As 
previously shown for VEGF-A165 
25
, this 
process might contribute to attenuated 
angiogenesis and tissue growth, which is a 
hallmark of chronic skin ulcers, the most 
common cause of impaired healing conditions 
in humans. 
The findings reported here might be of 
relevance for the development of PlGF-based 
concepts of therapeutic vascular growth in the 
field of regenerative medicine.  Current 
molecular/cellular based therapeutic 
angiogenesis trials showed only limited 
beneficial effects for some patients with 
ischemic diseases and there is a need for the 
development of alternative treatment strategies 
42
.  In pre-clinical studies PlGF has been 
shown to be a potent inducer of tissue 
vascularization 
1,3,9,43 
often without the side 
effects reported for VEGF-A therapy.  
Therefore, PlGF alone or in combination with 
other pro-angiogenic factors has been proposed 
for angiogenic therapies.  Based on our 
findings we propose the use of the PlGF-2 
isoform due to its superior activity, when 
compared to PlGF-1.  Moreover, in conditions 
of unrestrained inflammation with unbalanced 
proteases we suggest to protect PlGF-2 from 
proteolytic processing to maintain its integrity 
and biological activity. 
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FIGURE LEGENDS 
FIGURE 1. PlGF is cleaved by plasmin. (A-D) PlGF-1 and -2 were incubated with plasmin and 2-
antiplasmin (2-AP) for different time periods, subjected to non-reducing or reducing gel-
electrophoresis and analyzed by (A-C) silver-staining and (D) Western blotting.  (E) Quantification 
(ELISA) of endogenous PlGF protein in exudates obtained from healing or non-healing human 
wounds and blood serum; each dot represents a sample of a different patient. (F) Representative 
Western blot analysis of PlGF-2 incubated without/with plasmin or spiked into wound exudates. (G) 
Shown is a representative Western blot analysis of PlGF-2 incubated without/with plasmin or spiked 
into wound exudates pre-incubated without/with  2-AP and the mean fraction of intact/fragmented 
PlGF-2 SEM of multiple blots (n=3).  (A-F: PlGF proteins were expressed in Sf9 cells; G: PlGF-2 
protein was expressed in HEK293 cells). 
 
FIGURE 2. Identification of plasmin cleavage sites in PlGF-2 by LC-MS/MS analysis. PlGF-2 
(expressed in HEK293 cells) was incubated with plasmin and peptide fragments were analyzed by LC-
MS/MS. (A) Schematic presentation of plasmin cleavage sites (arrowheads) in PlGF-2 based on 
identified fragments; the HBD in PlGF-2 and VEGF-A165 is illustrated in grey; alignment of plasmin 
cleavage sites closest to the amino-terminus of VEGFA165, PlGF-1 and-2.  (B) Absolute and relative 
deviation between expected and found molecular weight of PlGF-2 peptide fragments identified by 
LC-MS/MS. 
 
FIGURE 3. PlGF-isoforms expressed in HEK293 cells are biologically active. (A) SDS-PAGE and 
Coomassie stain, and (B) CD-spectroscopy of PlGF-isoforms expressed in HEK293 cells. (C) 
Stimulation of HUVE cells with PlGF-isoforms (2.5 nM) and analysis of VEGFR-1 phosphorylation 
(Tyr1213); the degree of phosphorylation was determined by densitometric analysis of phospho-signal 
intensity and normalized to the corresponding -actin signal. 
 
FIGURE 4. Plasmin-cleavage attenuates PlGF-2-mediated endothelial cell chemotaxis and 
vascular sprouting.  (A) ConA pulldown and Western blot analysis of Nrp-1 expression in 
untransfected or human Nrp-1-transfected PAE cells. (B-D) Analysis of chemotactic activity of PlGF 
isoforms in a boyden chamber assay; PAE, PAE/Nrp-1 or HUVE cells were stimulated with (B) PlGF-
isoforms (produced in Sf9 insect cells) with or without plasmin and/or α2-antiplasmin and (C, D) 
PlGF-isoforms (expressed in HEK293 cells); samples were analyzed in triplicates in at least 3 
independent experiments, results are shown ±SEM (n  3); hpf, high power field.  (E)  Representative 
images of HUVE cell spheroids embedded in collagen gels and stimulated with various PlGF isoforms 
(3.66 nM) (expressed in HEK293 cells), VEGF-A165 (1 nM) (positive control) or 0.1% FCS (negative 
control) for 24 h. (F) Quantitative analysis of cumulative sprout length/spheroid and number of 
sprouts/spheroid; 15 spheroids/condition were analyzed in 3 independent experiments; results are 
shown ±SEM; scale bar 100 µm. 
 
FIGURE 5. The HBD promotes PlGF-2-induced granulation tissue formation in diabetic mice. 
(A) Representative H&E staining of PlGF-treated wound tissues of diabetic mice day 14 post injury; 
right panel presents boxed area in the left panel at higher magnification; dashed line outlines area of 
granulation tissue; e epidermis, d dermis, gt granulation tissue, sft subcutaneous fat tissue, white 
asterisks indicate blood vessels; scale bar 500 µm (left panel) and 100 µm (right panel); morphometric 
analysis of (B) area of granulation tissue and (C) quantification of F4/80
+
 stained cells within a 
defined area (high power field, hpf) within the granulation tissue of PlGF-treated wound tissues at day 
10 and day 14 post injury.  Each dot represents a different wound tissue, PlGF proteins were expressed 
in HEK293 cells. 
 
FIGURE 6. The HBD promotes PlGF-2-induced wound angiogenesis and recruitment of 
perivascular cells.  (A) Representative immunohistochemical staining for endothelial cells (CD31) 
and perivascular cells (desmin) of PlGF-treated wound tissues in diabetic mice at day 14 post injury. 
(B) Quantification of the area within the granulation tissue that stained positive for CD31 or desmin at 
day 10 and day 14 post injury; coverage of vessels with pericytes was quantified by calculating the 
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ratio of desmin/CD31 double stained area; dotted line indicates epidermal-dermal junction; e, 
epidermis; scale bar 100 µm, PlGF proteins were expressed in HEK293 cells. 
 
FIGURE 7. Binding analysis of PlGF isoforms to heparin or Nrp-1.  (A) To test whether PlGF-1, 
PlGF-2 or PlGF118 bind to heparin, the proteins (expressed in HEK293 cells) were dialyzed against 
50 mM NaCl and applied to heparin-sepharose column. Only PlGF-2 bound to heparin and was eluted 
with 1-2 M NaCl.  (B) Nrp-1 was immobilized on sensor chips and binding sensorgrams were 
recorded for PlGF variants as soluble analyte; different concentrations of PlGF proteins (3-300 nM) 
were monitored by measuring the variation in the plasmon resonance angle as function of time and 
described as response units (RU). Curves are shown in ascending order depending on the analyte´s 
concentration. 
  
FIGURE 8. The HBD promotes PlGF-2-induced phosphorylation of focal adhesion kinase, but is 
dispensable for Erk-1/-2 or Akt-mediated signaling. Western blot analysis of signal transduction in 
(A) HUVE cells, (B, C) PAE/Nrp-1 or (C) PAE cells stimulated with PlGF-2, PlGF118 or VEGF-
A165. Samples were subjected to SDS-PAGE and phosphorylation was analyzed by antibodies 
directed against phospho-Erk-1/-2 (Thr202/Tyr204), phospho-Akt (Ser473) or phospho-FAK 
(Tyr576/Tyr577). Antibodies directed against total proteins or β-actin served as loading control and were 
used to determine the increase over negative control. Shown are representative Western blots and the 
mean signal intensity SEM of multiple blots (n 3); PlGF proteins were expressed in HEK293 cells. 
(D) Model for PlGF-mediated activities in relation to amino acid sequences encoded by exon 6 and 7.  
(left)  PlGF-mediated phosphorylation of VEGFR-1 and downstream activation of Erk and Akt is 
independent of exon 6 and 7; (middle) exon 6 in PlGF-2 is essential for binding to heparin/HS or Nrp-
1; (right) it is hypothesized that Nrp-1/heparin binding promotes the interaction/clustering of PlGF-2 
with VEGFR-1 which then together with integrin activation leads to enhanced FAK activation and 
pro-angiogenic responses. 
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